Literature DB >> 15105104

Broth microdilution susceptibility testing for Leptospira spp.

Clinton K Murray1, Duane R Hospenthal.   

Abstract

Leptospirosis in humans has traditionally been treated with penicillin or doxycycline. The choice of therapy offered at the time of initial patient presentation is often empirical, as definitive diagnosis can take weeks. Determining the activity of numerous antimicrobial agents against a wide range of Leptospira serovars may broaden empirical therapeutic options. Various antimicrobials have been shown to be active against a limited number of serovars in in vitro studies, chiefly by the use of broth macrodilution techniques. We developed a broth microdilution technique using the commercially available growth indicator alamarBlue. MICs produced by this technique were compared to MICs and minimal bactericidal concentrations produced by the traditional broth macrodilution technique. The internal validity of our methods was assessed with 11 runs over numerous days with a single isolate of Leptospira interrogans serovar Icterohaemorrhagiae. By either method, the MICs for these internal-validity runs fell within 2 dilutions of each other for more than 90% of antimicrobials. A broader application of these two techniques included 12 serovars (including seven species) of Leptospira and six antimicrobials (penicillin G, doxycycline, chloramphenicol, erythromycin, cefotaxime, and ciprofloxacin). Observed reproducibility fell within 2 dilutions for 99% of the duplicate result sets for the MIC microdilution method, compared to 89% for the MIC macrodilution method. The macrodilution method tended to have a higher MIC at which 90% of the isolates were inhibited (MIC(90)) than did the microdilution method, but the MIC(90)s of both methods were within 2 dilutions of each other for all six drugs. The macrodilution and microdilution techniques produced similar results, with microdilution allowing a faster, more streamlined method of producing MIC results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105104      PMCID: PMC400540          DOI: 10.1128/AAC.48.5.1548-1552.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine.

Authors:  D P Alt; C A Bolin
Journal:  Am J Vet Res       Date:  1996-01       Impact factor: 1.156

2.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

3.  Cephalothin in the treatment of experimental leptospirosis in hamsters.

Authors:  R N Yoshimori; H S Goldberg; D C Blenden
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1965

4.  The susceptibility of a strain of Leptospira interrogans serogroup icterohaemorrhagiae to amoxycillin, erythromycin, lincomycin, tetracycline, oxytetracycline and minocycline.

Authors:  E S Broughton; L E Flack
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1986-07

5.  Penicillin therapy in icteric leptospirosis.

Authors:  C N Edwards; G D Nicholson; T A Hassell; C O Everard; J Callender
Journal:  Am J Trop Med Hyg       Date:  1988-10       Impact factor: 2.345

6.  Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis.

Authors:  A D Alexander; P L Rule
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans.

Authors:  I Takashima; M Ngoma; N Hashimoto
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Efficacy of ciprofloxacin against Leptospira interrogans serogroup icterohaemorrhagiae.

Authors:  I Shalit; A Barnea; A Shahar
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

9.  Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis.

Authors:  G Watt; L P Padre; M L Tuazon; C Calubaquib; E Santiago; C P Ranoa; L W Laughlin
Journal:  Lancet       Date:  1988-02-27       Impact factor: 79.321

10.  Ceftriaxone compared with sodium penicillin g for treatment of severe leptospirosis.

Authors:  Thanachai Panaphut; Somnuek Domrongkitchaiporn; Asda Vibhagool; Bandit Thinkamrop; Wattanachai Susaengrat
Journal:  Clin Infect Dis       Date:  2003-06-06       Impact factor: 9.079

View more
  18 in total

1.  In vitro and in vivo activity of first generation cephalosporins against Leptospira.

Authors:  Brande M Harris; Peter J Blatz; Mary K Hinkle; Suzanne McCall; Miriam L Beckius; Katrin Mende; Janelle L Robertson; Matthew E Griffith; Clinton K Murray; Duane R Hospenthal
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

2.  In vitro sensitivity and resistance of 46 Leptospira strains isolated from rats in the Philippines to 14 antimicrobial agents.

Authors:  Antara Chakraborty; Satoshi Miyahara; Sharon Y A M Villanueva; Nina G Gloriani; Shin-Ichi Yoshida
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

3.  Antibiotic resistance markers for genetic manipulations of Leptospira spp.

Authors:  Dante Poggi; Priscila Oliveira de Giuseppe; Mathieu Picardeau
Journal:  Appl Environ Microbiol       Date:  2010-05-28       Impact factor: 4.792

4.  Efficacy of macrolides and telithromycin against leptospirosis in a hamster model.

Authors:  James E Moon; Michael W Ellis; Michael C Ellis; Matthew E Griffith; Joshua S Hawley; Robert G Rivard; Suzanne McCall; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.

Authors:  Matthew E Griffith; James E Moon; Erica N Johnson; Kyra P Clark; Joshua S Hawley; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

6.  Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.

Authors:  Roseanne A Ressner; Matthew E Griffith; Miriam L Beckius; Guillermo Pimentel; R Scott Miller; Katrin Mende; Susan L Fraser; Renee L Galloway; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

7.  Screening of a Leptospira biflexa mutant library to identify genes involved in ethidium bromide tolerance.

Authors:  Helena Pětrošová; Mathieu Picardeau
Journal:  Appl Environ Microbiol       Date:  2014-07-25       Impact factor: 4.792

8.  A widely conserved bacterial cytoskeletal component influences unique helical shape and motility of the spirochete Leptospira biflexa.

Authors:  Katrina M Jackson; Cindi Schwartz; Jenny Wachter; Patricia A Rosa; Philip E Stewart
Journal:  Mol Microbiol       Date:  2018-02-13       Impact factor: 3.501

9.  Potential anti-leptospiral compound, leptomycin B from marine Streptomyces indiaensis MSU5: taxonomy, fermentation, compound isolation, in vitro and in vivo efficacy.

Authors:  Jeyaraman Thirumalairaj; Karikalacholan Sivasankari; Kalimuthusamy Natarajaseenivasan; Ramasamy Balagurunathan
Journal:  World J Microbiol Biotechnol       Date:  2017-09-27       Impact factor: 3.312

10.  Determination of susceptibilities of 26 Leptospira sp. serovars to 24 antimicrobial agents by a broth microdilution technique.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.